Propeller Health has received 510(k) clearance from the FDA to market the Propeller inhaler monitoring platform for use with the Diskus DPI and with the Respimat SMI, the company announced. Two versions of the Propeller platform have previously been approved for use with MDIs, most recently in 2014.
The platform includes Bluetooth-enabled sensors that snap onto the devices paired with a mobile app that provides feedback to patients and their physicians. The system is being used in the AIR Louisville program, which is collecting data on asthma triggers across the city of Louisville, KY.
Propeller CEO and Co-Founder David Van Sickle said, “Today we’re excited to announce back-to-back FDA clearances that demonstrate our leadership and commitment to a singular goal: moving the field of respiratory health forward. 510(k) clearance of our platform with inhaler devices from leading global respiratory companies GlaxoSmithKline and Boehringer Ingelheim opens the door for millions of patients to expect and achieve something better in asthma and COPD.”
Read the Propeller press release.
